An Extended Access Program for Perampanel
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01871233|
Expanded Access Status : Available
First Posted : June 6, 2013
Last Update Posted : December 17, 2018
The Extended Access Program (EAP) is a managed access programme for Perampanel. The main objective of this EAP is to ensure that patients participating in studies E2007-A001-207, E2007-G000-307, or E2007-G000-235 continue to have access to perampanel until such time perampanel tablets become commercially available for the treatment of Partial Onset Seizures (POS) in the country in which they reside. This EAP will consist of 2 phases:
- Screening: The patient will start the program once the Screening assessments are completed and the patient is qualified for participation.
- Treatment: Additional assessments, physical examinations, and dosage changes will be clinically determined by the treating physician.
Patients will enter this program on the same dose of perampanel that they were receiving at the end of their participation in previous study. Doses of perampanel and of concomitant anti-epileptic drugs (AEDs) can be adjusted (i.e., added,removed, or changed in dose) based on clinical judgment.
Treatment will be prescribed as long as clinically appropriate according to the judgement of the treating physician and the approved Summary of Product Characteristics (SmPC).
The program will complete in a staggered fashion, country by country, as and when perampanel becomes commercially available for the treatment of POS in each country.
|Condition or disease||Intervention/treatment|
|Partial Onset Seizures||Drug: Perampanel|
|Study Type :||Expanded Access|
|Official Title:||An Extended Access Program for Perampanel|
- Drug: Perampanel
Patients will enter this program on the same dose of perampanel that they were receiving at the end of their participation in Studies 207, 307, or 235. Doses of perampanel and of concomitant anti-epileptic drugs (AEDs) can be adjusted based on clinical judgment. A minimum daily dose permitted will be 12 mg per day. Treatment will be prescribed as long as clinically appropriate according to the judgment of the treating physician and the approved summary of Product Characteristics (SmPC). Tablets will be available in strengths of 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg. Patients will be instructed to take their perampanel tablets once daily, by mouth, before bedtime, and with food.Other Name: E2007
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01871233
|Contact: Eisai Eisai Medical Informationemail@example.com|
Show 78 Study Locations
|Study Director:||Karen Searle, PhD||Eisai Limited|